Malignancies associated with chronic hepatitis C: Case report and review of the literature

Netherlands Journal of Medicine

Volumn 69, Issue 5, 2011, Pages 211-215

  Vlaar, A P J ^a,b   Rietdijk, S T ^c   Zeerleder, S S ^d   Boerman, T ^e   Beuers, U ^c  

^a Departments of Internal Medicine and Geriatric Medicine   (Netherlands)

^b Departments of Intensive Care Medicine   (Netherlands)

^c Departments of Gastroenterology and Hepatology   (Netherlands)

^d Departments of Hematology   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DOXORUBICIN; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LACTATE DEHYDROGENASE; M PROTEIN; MYC PROTEIN; PEGINTERFERON; PROTEIN BCL 6; RIBAVIRIN;

ABDOMINAL PAIN; AGED; ASCITES; AUTOPSY; B CELL LYMPHOMA; BILE DUCT CARCINOMA; CASE REPORT; CHEMOEMBOLIZATION; CHOLELITHIASIS; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DISEASE ASSOCIATION; GENOTYPE; HEART MUSCLE ISCHEMIA; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; LAPAROTOMY; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MEAN CORPUSCULAR VOLUME; MULTIPLE ORGAN FAILURE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; NURSING HOME; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; REVIEW; SHOCK; SMALL INTESTINE PERFORATION; STOMACH ULCER; THROMBOCYTE COUNT;

AGED; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; RISK FACTORS;

EID: 79961230200     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-74.
2. Chang KY, Chang JY, Yen Y. Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw. 2009;7:423-7.
3. De Vita S, Sansonno D, Dolcetti R, et al. Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. Blood. 1995;86:1887-92.
4. Krishnan C. Lymphoplasmacytic lymphoma arising in the setting of hepatitis C and mixed cryoglobulinemia. J Clin Oncol. 2007;25:4312-4.
5. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327:1490-5.
6. De Re V, De Vita S, Marzotto A, et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood. 2000;96:3578-84.
7. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference. Hepatocellular carcinoma. Ann Intern Med. 1988;108:390-401.
8. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997;26:34S-8S.
9. Slavenburg S, Verduyn-Lunel FM, Hermsen JT, Melchers WJ, te Morsche RH, Drenth JP. Prevalence of hepatitis C in the general population in the Netherlands. Neth J Med. 2008;66:13-7.
10. van Hattum J. Health strategy on HCV in The Netherlands. Acta Gastroenterol Belg. 2002;65:115-7.
11. Castells L, Vargas V, Gonzalez A, Esteban J, Esteban R, Guardia J. Long interval between HCV infection and development of hepatocellular carcinoma. Liver. 1995;15:159-63.
12. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-50.
13. Pang PS, Planet PJ, Glenn JS. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One. 2009;4:e6579.
14. Nishida N. Impact of hepatitis virus and aging on DNA methylation in human hepatocarcinogenesis. Histol Histopathol. 2010;25:647-54.
15. de Fost M, vom Dahl S, Weverling GJ, et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis. 2006;36:53-8.
16. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313:1256-62.
17. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820-32.
18. Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut. 2010;59:1303-7.
19. Tanash HA, Nilsson PM, Nilsson JA, Piitulainen E. Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ). Thorax. 2008;63:1091-5.
20. Teufel A, Weinmann A, Centner C, et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol. 2009;15:578-82.
21. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27:1435-40.
22. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119:312-23.
23. Shin HR, Oh JK, Masuyer E, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010;101:579-85.
24. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis. 1994;14:109-14.
25. Mendes F, Lindor KD. Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol. 2010;7:611-9.
26. Braconi C, Patel T. Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infect Dis Clin North Am. 2010;24:871-84, vii.
27. Li T, Li D, Cheng L, Wu H, et al. Epithelial-mesenchymal transition induced by hepatitis C virus core protein in cholangiocarcinoma. Ann Surg Oncol. 2010;17:1937-44.
28. Roskams T. Different types of liver progenitor cells and their niches. J Hepatol. 2006;1:1-4.
29. Agarwal K, Agarwal S. Helicobacter pylori vaccine: from past to future. Mayo Clin Proc. 2008;83:169-75.
30. Kutok JL, Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol. 2006;1:375-404.
31. Della RA, Baldini C, Tavoni A, Bombardieri S. How HCV has changed the approach to mixed cryoglobulinemia. Clin Exp Rheumatol. 2009;27:S115-S123.
32. Lapinski TW, Parfieniuk A, Rogalska-Plonska M, Czajkowska J, Flisiak R. Prevalence of cryoglobulinaemia in hepatitis C virus- and hepatitis C virus/human immunodeficiency virus-infected individuals: implications for renal function. Liver Int. 2009;29:1158-61.
33. Agnello V. The aetiology of mixed cryoglobulinaemia associated with hepatitis C virus infection. Scand J Immunol. 1995;42:179-84.
34. Invernizzi F. Secondary and essential cryoglobulinemias. Frequency, nosological classification, and long-term follow-up. Acta Haematol. 1983;70:73-82.
35. Gisbert JP, Garcia-Buey L, Arranz R, et al. The prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Eur J Gastroenterol Hepatol. 2004;16:135-8.
36. Dal ML, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15:2078-85.
37. Engels EA, Chatterjee N, Cerhan JR, et al. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study. Int J Cancer. 2004;111:76-80.
38. Zuckerman E, Zuckerman T, Levine AM, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med. 1997;127:423-8.
39. Andreone P, Zignego AL, Cursaro C, et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med. 1998;129:294-8.
40. Landau DA, Saadoun D, Calabrese LH, Cacoub P. The pathophysiology of HCV induced B-cell clonal disorders. Autoimmun Rev. 2007;6:581-7.
41. Mazzaro C, Franzin F, Tulissi P, et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer. 1996;77:2604-13.
42. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347:89-94.
43. Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11:827-34.
44. Franceschi S, Lise M, Trepo C, et al. Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol Biomarkers Prev. 2011;20:208-14.